US-Based Eli Lilly to Fund US Phase 1 Study for Laekna's Weight Loss Drug

Like
Comment
Favorite

US-Based Eli Lilly to Fund US Phase 1 Study for Laekna's Weight Loss Drug

MT Newswires Live2024-11-20

US-based drug company Eli Lilly will finance a phase 1 study in the US for Laekna's (HKG:2105) LAE102 anti-obesity drug, according to a Wednesday filing with the Hong Kong Exchange.

The drug helps target the ActRIIA receptor that helps with muscle regeneration and lipid metabolism, the filing said.

Preclinical trials showed the drug helps boost muscular mass and decreases fat, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

19:50
Nyse Order Imbalance 41326.0 Shares on Sell Side
19:33
Exclusive-the BOT Company, Building at-Home Robots, Valued at $2 Billion With Zero Revenue, Sources Say
19:33
Exclusive-Former Cruise CEO Raises $150 Million for New Robotics Startup, Sources Say
19:32
Investigation Will Focus on Electrical Distribution Equipment - London Fire Brigade
19:32
Fire at Substation Near Heathrow Airport Is Believed to Be Non-Suspicious - London Fire Brigade

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2484116259?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-20 17:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484116259","market":"fut","top_or_hot":-1,"title":"US-Based Eli  Lilly to Fund US Phase 1 Study for Laekna's Weight Loss Drug","media":"MT Newswires Live","content":"<html><body><p> US-based drug company Eli Lilly will finance a phase 1 study in the US for Laekna's (HKG:2105) LAE102 anti-obesity drug, according to a Wednesday filing with the Hong Kong Exchange.</p><p>The drug helps target the ActRIIA receptor that helps with muscle regeneration and lipid metabolism, the filing said.</p><p>Preclinical trials showed the drug helps boost muscular mass and decreases fat, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US-Based Eli  Lilly to Fund US Phase 1 Study for Laekna's Weight Loss Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS-Based Eli  Lilly to Fund US Phase 1 Study for Laekna's Weight Loss Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-20 17:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> US-based drug company Eli Lilly will finance a phase 1 study in the US for Laekna's (HKG:2105) LAE102 anti-obesity drug, according to a Wednesday filing with the Hong Kong Exchange.</p><p>The drug helps target the ActRIIA receptor that helps with muscle regeneration and lipid metabolism, the filing said.</p><p>Preclinical trials showed the drug helps boost muscular mass and decreases fat, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484116259","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484116259","pubTimestamp":1732094949,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"US-based drug company Eli Lilly will finance a phase 1 study in the US for Laekna's  LAE102 anti-obesity drug, according to a Wednesday filing with the Hong Kong Exchange.The drug helps target the ActRIIA receptor that helps with muscle regeneration and lipid metabolism, the filing said.Preclinical trials showed the drug helps boost muscular mass and decreases fat, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02105":"来凯医药-B"},"translate_title":"美国礼来公司将资助Laekna减肥药在美国的一期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":0.9},"content_text":"US-based drug company Eli Lilly will finance a phase 1 study in the US for Laekna's (HKG:2105) LAE102 anti-obesity drug, according to a Wednesday filing with the Hong Kong Exchange.The drug helps target the ActRIIA receptor that helps with muscle regeneration and lipid metabolism, the filing said.Preclinical trials showed the drug helps boost muscular mass and decreases fat, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}